Cargando…
Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
The amount of evidence for guideline‐directed new heart failure (HFrEF) disease‐modifying drugs in the context of chronic kidney disease (CKD) is relatively modest, especially in end‐stage CKD. We report a case of dramatic reverse remodelling and disease regression in a naïve HFrEF young woman on ha...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192298/ https://www.ncbi.nlm.nih.gov/pubmed/36907832 http://dx.doi.org/10.1002/ehf2.14344 |
_version_ | 1785043599195373568 |
---|---|
author | Mapelli, Massimo Mantegazza, Valentina Ferrari, Cristina Cimino, Roberto Maragna, Riccardo Pontone, Gianluca Pepi, Mauro Agostoni, Piergiuseppe |
author_facet | Mapelli, Massimo Mantegazza, Valentina Ferrari, Cristina Cimino, Roberto Maragna, Riccardo Pontone, Gianluca Pepi, Mauro Agostoni, Piergiuseppe |
author_sort | Mapelli, Massimo |
collection | PubMed |
description | The amount of evidence for guideline‐directed new heart failure (HFrEF) disease‐modifying drugs in the context of chronic kidney disease (CKD) is relatively modest, especially in end‐stage CKD. We report a case of dramatic reverse remodelling and disease regression in a naïve HFrEF young woman on haemodialysis treated with sacubitril/valsartan and SGLT2i. At 10‐month follow‐up, the patient normalized left ventricle and atrial volumes and improved ejection fraction to the normal range, assessed both by echocardiography and cardiac magnetic resonance. Cardiac biomarkers and exercise performance improved consensually. The haemodialysis protocol and the loop diuretic dose were unchanged within the whole period. |
format | Online Article Text |
id | pubmed-10192298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101922982023-05-19 Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i Mapelli, Massimo Mantegazza, Valentina Ferrari, Cristina Cimino, Roberto Maragna, Riccardo Pontone, Gianluca Pepi, Mauro Agostoni, Piergiuseppe ESC Heart Fail Case Report The amount of evidence for guideline‐directed new heart failure (HFrEF) disease‐modifying drugs in the context of chronic kidney disease (CKD) is relatively modest, especially in end‐stage CKD. We report a case of dramatic reverse remodelling and disease regression in a naïve HFrEF young woman on haemodialysis treated with sacubitril/valsartan and SGLT2i. At 10‐month follow‐up, the patient normalized left ventricle and atrial volumes and improved ejection fraction to the normal range, assessed both by echocardiography and cardiac magnetic resonance. Cardiac biomarkers and exercise performance improved consensually. The haemodialysis protocol and the loop diuretic dose were unchanged within the whole period. John Wiley and Sons Inc. 2023-03-12 /pmc/articles/PMC10192298/ /pubmed/36907832 http://dx.doi.org/10.1002/ehf2.14344 Text en © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Case Report Mapelli, Massimo Mantegazza, Valentina Ferrari, Cristina Cimino, Roberto Maragna, Riccardo Pontone, Gianluca Pepi, Mauro Agostoni, Piergiuseppe Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i |
title | Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i |
title_full | Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i |
title_fullStr | Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i |
title_full_unstemmed | Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i |
title_short | Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i |
title_sort | dramatic disease regression in a case of hfref with end‐stage renal failure treated with sacubitril/valsartan and sglt2i |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192298/ https://www.ncbi.nlm.nih.gov/pubmed/36907832 http://dx.doi.org/10.1002/ehf2.14344 |
work_keys_str_mv | AT mapellimassimo dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i AT mantegazzavalentina dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i AT ferraricristina dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i AT ciminoroberto dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i AT maragnariccardo dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i AT pontonegianluca dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i AT pepimauro dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i AT agostonipiergiuseppe dramaticdiseaseregressioninacaseofhfrefwithendstagerenalfailuretreatedwithsacubitrilvalsartanandsglt2i |